Ground News

News from curetoday.com

See all of curetoday.com news coverage in one place. Discover how curetoday.com’s media bias informs their coverage and compare with thousands of other news outlets.

We’ve discovered 415 headlines written by curetoday.com during the past 3 months.

We’ve assigned a media bias rating of unknown to curetoday.com. You can read more about our methodology here.

curetoday.com’s aggregated factuality score is Unknown. Factuality is assigned by combining fact check, credibility, and reliability ratings from Ad Fontes Media and Media Bias/Fact Check.

Information about curetoday.com

Where is curetoday.com located?curetoday.com's Website

Media Bias Ratings

Do you diasgree?

Edit bias

Learn more about Media Bias Ratings.

Factuality

Learn more about Factuality Ratings

Reveal Factuality Ratings by upgrading to a Premium account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Ownership

Learn more about Ownership categories

Reveal Ownership Data by upgrading to a Vantage account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Top curetoday.com News

Breast Cancer · United States

Gilead's Trodelvy, with Keytruda, cuts breast cancer risk by 35% in trial

70% Center coverage: 17 sources

Gilead Sciences´ Trodelvy in combination with Merck's blockbuster immunotherapy Keytruda lowered the risk of an aggressive type of breast cancer worsening by 35% when used as an initial treatment, according to results of a large trial presented on Saturday. The data is likely to change how patients are treated following a diagnosis for advanced triple-negative breast cancer, one expert said.See the Story

Cancer · United Kingdom

Immunotherapy drug doubles survival rate for head and neck cancer in breakthrough trial

50% Center coverage: 8 sources

See the Story

Breast Cancer

Arvinas and Pfizer's Vepdegestrant Significantly Improves Progression-Free Survival for ...

86% Center coverage: 7 sources

Pivotal Phase 3 VERITAC-2 clinical trial results presented at ASCO demonstrate 2.9-month improvement in median progression-free survival when compared to fulvestrant in second line-plus patients with an estrogen receptor 1 mutationVepdegestrant was generally well tolerated, with few discontinuations and low…See the Story

News from curetoday.com

News from curetoday.com

Information about curetoday.com

Media Bias Ratings

Factuality

Ownership

Top curetoday.com News

Gilead's Trodelvy, with Keytruda, cuts breast cancer risk by 35% in trial

Immunotherapy drug doubles survival rate for head and neck cancer in breakthrough trial

Arvinas and Pfizer's Vepdegestrant Significantly Improves Progression-Free Survival for ...

Similar News Topics

Topics Most Covered by curetoday.com

Sources Covering Similar Topics

Breaking News Topics Related to curetoday.com

Breaking News Topics Related to curetoday.com

Similar News Topics

Top curetoday.com News

Gilead's Trodelvy, with Keytruda, cuts breast cancer risk by 35% in trial

Immunotherapy drug doubles survival rate for head and neck cancer in breakthrough trial

Arvinas and Pfizer's Vepdegestrant Significantly Improves Progression-Free Survival for ...

New three-drug combination could help women with aggressive breast cancer live longer, study suggests

Precision Pfizer Drug Leads to ‘Unprecedented’ Survival in Colorectal Cancer, Data at ASCO Show

Camizestrant Enhances PFS vs AI Inhibitor in ER+/HER2– Breast Cancer

Adding Immunotherapy to Chemotherapy After Surgery Improves Survival in Colon Cancer

Breakthrough in Stomach Cancer Prevention

Rapid Developments to Enhance Patient Experience in GU Cancer

Additive Antihistamines May Improve Metastatic Bladder Cancer Outcomes

Delving into the Evaluation of JNJ-1900 Trial for Lung Cancer Treatment